|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-8-4
|
|
pubmed:abstractText |
To compare the efficacy and tolerance of sequential versus alternate front-line administration of cisplatin-etoposide (PE) and topotecan (T) in patients with extensive stage small cell lung cancer (SCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1791-7530
|
|
pubmed:author |
pubmed-author:AgelakiSophiaS,
pubmed-author:AgelidouAthinaA,
pubmed-author:AgelidouMariaM,
pubmed-author:AndroulakisNikolaosN,
pubmed-author:BakaSophiaS,
pubmed-author:GeorgouliasVassilisV,
pubmed-author:GerogianniAlekaA,
pubmed-author:KalbakisKostasK,
pubmed-author:KotsakisAthanasiosA,
pubmed-author:MavroudisDimitrisD,
pubmed-author:PapakotoulasPavlosP,
pubmed-author:PavlakouGeorgiaG,
pubmed-author:TsarouchaEmilyE,
pubmed-author:VamvakasLambrosL,
pubmed-author:VeslemesMarinosM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3031-8
|
|
pubmed:meshHeading |
pubmed-meshheading:20683051-Adult,
pubmed-meshheading:20683051-Aged,
pubmed-meshheading:20683051-Aged, 80 and over,
pubmed-meshheading:20683051-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20683051-Cisplatin,
pubmed-meshheading:20683051-Disease Progression,
pubmed-meshheading:20683051-Drug Administration Schedule,
pubmed-meshheading:20683051-Etoposide,
pubmed-meshheading:20683051-Female,
pubmed-meshheading:20683051-Humans,
pubmed-meshheading:20683051-Lung Neoplasms,
pubmed-meshheading:20683051-Male,
pubmed-meshheading:20683051-Middle Aged,
pubmed-meshheading:20683051-Patient Compliance,
pubmed-meshheading:20683051-Small Cell Lung Carcinoma,
pubmed-meshheading:20683051-Survival Rate,
pubmed-meshheading:20683051-Topotecan
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.
|
|
pubmed:affiliation |
Hellenic Oncology Research Group (HORG), 55 Lomvardou Str, 11470, Athens, Greece.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
